A Phase II study of ERK inhibition by ulixertinib (BVD-523) in Metastatic Uveal Melanoma

CONCLUSIONS: ERK inhibition with ulixertinib (BVD-523) did not demonstrate activity in patients with metastatic uveal melanoma. The toxicities observed were consistent with what would be expected with MAPK pathway inhibition.PMID:38683104 | DOI:10.1158/2767-9764.CRC-24-0036

Source: Biomed Res - April 29, 2024 Category: Research Authors: Elizabeth I Buchbinder Justine V Cohen Giuseppe Tarantino Christine G Lian David Liu Rizwan Haq F Stephen Hodi Donald P Lawrence Anita Giobbie-Hurder Deborah Knoerzer Ryan J Sullivan Source Type: research